Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
STAAR Surgical Company is a medical instruments & supplies business based in the US. STAAR Surgical Company shares (STAA) are listed on the NASDAQ and all prices are listed in US Dollars. STAAR Surgical Company employs 575 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$126.15|
|52-week range||$60.31 - $163.08|
|50-day moving average||$136.32|
|200-day moving average||$133.93|
|Wall St. target price||$147.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.41|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||9.80%|
|1 month (2021-09-22)||-11.97%|
|3 months (2021-07-22)||-5.53%|
|6 months (2021-04-22)||-3.07%|
|1 year (2020-10-22)||68.90%|
|2 years (2019-10-22)||360.40%|
|3 years (2018-10-22)||202.30%|
|5 years (2016-10-21)||1,234.92%|
Valuing STAAR Surgical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of STAAR Surgical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
STAAR Surgical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 282x. In other words, STAAR Surgical Company shares trade at around 282x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
STAAR Surgical Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.3 million.
The EBITDA is a measure of a STAAR Surgical Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$206.2 million|
|Operating margin TTM||13.1%|
|Gross profit TTM||$119.6 million|
|Return on assets TTM||6.59%|
|Return on equity TTM||10.15%|
|Market capitalisation||$5.4 billion|
TTM: trailing 12 months
There are currently 1.7 million STAAR Surgical Company shares held short by investors – that's known as STAAR Surgical Company's "short interest". This figure is 6% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting STAAR Surgical Company shares can be evaluated.
STAAR Surgical Company's "short interest ratio" (SIR) is the quantity of STAAR Surgical Company shares currently shorted divided by the average quantity of STAAR Surgical Company shares traded daily (recently around 338439.07815631). STAAR Surgical Company's SIR currently stands at 4.99. In other words for every 100,000 STAAR Surgical Company shares traded daily on the market, roughly 4990 shares are currently held short.
However STAAR Surgical Company's short interest can also be evaluated against the total number of STAAR Surgical Company shares, or, against the total number of tradable STAAR Surgical Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case STAAR Surgical Company's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 STAAR Surgical Company shares in existence, roughly 40 shares are currently held short) or 0.0439% of the tradable shares (for every 100,000 tradable STAAR Surgical Company shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against STAAR Surgical Company.
Find out more about how you can short STAAR Surgical Company stock.
We're not expecting STAAR Surgical Company to pay a dividend over the next 12 months.
STAAR Surgical Company's shares were split on a 1:2 basis on 17 May 1992. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your STAAR Surgical Company shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for STAAR Surgical Company shares which in turn could have impacted STAAR Surgical Company's share price.
Over the last 12 months, STAAR Surgical Company's shares have ranged in value from as little as $60.31 up to $163.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while STAAR Surgical Company's is 1.0677. This would suggest that STAAR Surgical Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.